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Feasible HCV targets 
in Egypt
Romulus Breban and colleagues 
(September issue) present modelling 
results of hepatitis C virus (HCV) 
interventions in Egypt.1 They suggest 
focusing interventions on people who 
regularly receive medical injections to 
achieve the greatest epidemiological 
eﬀ ect on HCV transmission. However, 
we believe that universal treatment 
at 2·5 or even 15 years after infection 
(as presented in figure 5)1 is highly 
ambitious, as it would necessitate 
immediate identification and 
treatment of most of the people living 
with hepatitis C in Egypt. This process 
would demand substantial resources 
and the removal of many practical 
barriers. Although the proposed 
treatment coverage of the core group 
seems to be achievable, we would 
like to see the focused intervention 
analysed with more realistic general 
levels of treatment coverage to guide 
operational implementation. 
Breban and colleagues previously 
reported2 that the prevalence of HCV 
in people younger than 50 years in 
Egypt fell substantially between 1996 
and 2004. This finding implies the 
HCV-infected population is ageing 
and that age is highly important in the 
progression of the epidemic, aﬀ ecting 
future prevalence and thus continuing 
transmission. Decreasing prevalence is 
supported by evidence of falling HCV 
seroprevalence among blood donors, 
from 17·7% in 2000 to 7·6% in 2007.3 
In Breban and colleagues’ modelling 
analysis,1 incidence was estimated 
from earlier data (2001–06)4 and age 
eﬀ ects were excluded. As a result, the 
basic reproduction numbers calculated 
by Breban and colleagues might be 
overestimates, suggesting that less 
ambitious interventions might be 
suﬃ  cient to control the HCV epidemic. 
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